An Early Disease Activity Composite Can Predict Long-Term Disease Outcome in CHAMPIONS (PD5.010)

Abstract

Objective: To compare long-term outcomes in groups categorized based on a composite of short-term disease activity parameters in the CHAMPIONS 5-year cohort. Background The ability to use short-term parameters to identify individuals at risk for poor long-term outcomes would help clinicians select optimal treatments for multiple sclerosis (MS) patients. Design/Methods: CHAMPIONS 5-year was an open-label extension study enrolling 203 (53%) of the patients from CHAMPS. In CHAMPS, patients received immediate treatment (IT) or delayed treatment (DT) with intramuscular interferon beta-1a (IM IFNβ-1a). Progression to clinically definite MS (CDMS) and magnetic resonance imaging (MRI) activity within the first 6 months of CHAMPS formed composites that defined therapeutic target achieved (TTA) ( Results: In the IT group, patients who met TTA criteria had better outcomes compared to TTNA patients. Mean Expanded Disability Status Scale (EDSS) change from month 6 to year 5 was -0.17 in TTA patients and 0.80 in TTNA patients (P=0.0009). Mean brain parenchymal fraction change was -0.010 in TTA patients and -0.017 in TTNA patients (P Conclusions: Use of clinical and imaging measures to monitor disease activity early in the disease course may help predict long-term outcomes for patients. Supported by: Biogen Idec Inc. Disclosure: Dr. Kinkel has received personal compensation for activities with Biogen Idec, Inc, Ironwood Pharmaceuticals, and Teva Neuroscience as a consultant. Dr. Kinkel has received personal compensation in an editorial capacity for Neurological Diseases. Dr. Kinkel has received research support from Biogen Idec. Dr. Simon has nothing to disclose. Dr. Waubant has received personal compensation for activities with Teva Neuroscience, Actelion, Sanofi-Aventis Pharmaceuticals, Roche Diagnostics Corporation and Biogen Idec as a speaker and/or consultant. Dr. Waubant has received research support from Biogen Idec and Sanofi-Aventis Pharmaceuticals. Dr. Fisher has received personal compensation for activities with Biogen Idec. Dr. Fisher has received research support from Biogen Idec and Genzyme. Dr. You has received personal compensation for activities with Biogen Idec as an employee.